KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for BeOne Medicines (ONC) over the last 11 years, with Q3 2025 value amounting to $140.8 million.

  • BeOne Medicines' Share-based Compensation rose 2276.61% to $140.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $494.7 million, marking a year-over-year increase of 1587.9%. This contributed to the annual value of $441.6 million for FY2024, which is 2012.96% up from last year.
  • According to the latest figures from Q3 2025, BeOne Medicines' Share-based Compensation is $140.8 million, which was up 2276.61% from $150.8 million recorded in Q2 2025.
  • BeOne Medicines' Share-based Compensation's 5-year high stood at $150.8 million during Q2 2025, with a 5-year trough of $45.8 million in Q1 2021.
  • Its 5-year average for Share-based Compensation is $91.6 million, with a median of $88.7 million in 2024.
  • As far as peak fluctuations go, BeOne Medicines' Share-based Compensation surged by 4303.01% in 2022, and later surged by 768.16% in 2025.
  • Over the past 5 years, BeOne Medicines' Share-based Compensation (Quarter) stood at $63.0 million in 2021, then increased by 23.99% to $78.1 million in 2022, then rose by 18.94% to $92.9 million in 2023, then increased by 15.82% to $107.6 million in 2024, then surged by 30.84% to $140.8 million in 2025.
  • Its Share-based Compensation stands at $140.8 million for Q3 2025, versus $150.8 million for Q2 2025 and $95.5 million for Q1 2025.